Product news from the 02/13/07 news brief

Share this article:
Pfizer said the FDA has approved new labeling of Sutent (sunitinib malate) which includes first-line treatment of advanced renal cell carcinoma, a type of advanced kidney cancer, based on results of a large Phase III trial, which showed prolonged progression-free survival. Mylan Laboratories and Barr Pharmaceuticals became the second and third drugmakers to receive FDA approval to sell generic versions of Pfizer’s blockbuster antidepressant Zoloft (sertraline). Both companies said they would begin shipping the product immediately. Pfizer lost patent protection on Zoloft last August. Branded Zoloft sales fell 79% in Pfizer’s fourth quarter to $166 million, compared with $808 million in the same period a year earlier. Teva Pharmaceutical was able to sell the only generic version during the first six months after expiration of Zoloft’s patent, under a federally enforced exclusivity period.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.